Sales of injectable anti-HIV therapeutics will reach $2.... The injectable ART are progressively getting more recognition as the industry is moving away from STRs(single-tablet regimens) due to medical adverse effects(osteoporosis and kidney disease), compliance and the stigma of the condition.
Trogarzo's IV push phase 3 trial(much more convenient than the current method of administration of the drug by infusion) will be concluded by end of 2021 and phase 2/3 Intramuscular Injection trial will be starting in coming weeks as per the company.
Sales of injectable anti-HIV therapeutics will reach $2 billion in 2029: GlobalData
"The human immunodeficiency virus (HIV) therapeutics market was worth an estimated $22.9 billion across the seven major markets (7MM*) in 2019. The market is expected to grow at a Compound Annual Growth Rate (CAGR) of two per cent, reaching $28 billion in 2029, according to GlobalData.
GlobalData’s latest report, ‘HIV Therapeutics: Global Drug Forecast and Market Analysis to 2029’, reveals that growth in the market will be driven by the entry of injectable therapies that can be administered intramuscularly or subcutaneously.
HIV-infected patients are normally managed with oral therapies. One type of treatment regimen involves the administration of one tablet per day. These single-tablet regimens (STRs) are made up of fixed-dose combinations of individual antiretroviral drugs.
Magdalene Crabbe, Senior Ophthalmology and Infectious Diseases Analyst at GlobalData, comments, The launch of STRs revolutionised the treatment landscape of HIV and met major unmet needs by increasing patient compliance and improving the safety and tolerability profiles of antiretroviral drugs. However, STRs are not without their issues. A key component of multiple drugs is tenofovir disoproxil fumarate (TDF), which has been linked to osteoporosis and kidney disease. There are also people who don’t remember to take their medication, and people who feel embarrassed about living with HIV, which lowers compliance.”
https://www.expresspharma.in/amp/market-pharma/sales-of-injectable-anti-hiv-therapeutics-will-reach-2-billion-in-2029-globaldata/